due
urgenc
demand
numer
sever
acut
respiratori
syndrom
coronaviru
sar
immunoassay
rapidli
develop
place
market
limit
valid
clinic
sampl
thorough
valid
serolog
test
requir
facilit
use
accur
diagnosi
infect
confirm
molecular
result
contact
trace
epidemiolog
studi
studi
evalu
sensit
specif
nine
commerci
avail
serolog
test
includ
three
enzymelink
immunosorb
assay
elisa
six
pointofcar
poc
later
flow
test
assay
valid
use
serum
sampl
pcrposit
patient
document
first
day
diseas
ii
archiv
sera
obtain
healthi
individu
emerg
china
iii
sera
patient
acut
viral
respiratori
tract
infect
caus
coronavirus
noncoronavirus
iv
sera
patient
posit
dengu
viru
cytomegaloviru
epstein
barr
viru
result
show
specif
wantai
total
antibodi
elisa
euroimmun
iga
elisa
euroimmun
igg
elisa
sensit
respect
overal
perform
poc
test
accord
manufactur
rank
order
autobio
diagnost
dynamik
biotechnolog
ctk
biotech
artron
laboratori
acro
biotech
hangzhou
alltest
biotech
overal
find
facilit
select
serolog
assay
detect
antibodi
toward
diagnosi
well
seroepidemiolog
vaccin
develop
studi
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
antibodi
detect
particularli
relev
later
stage
infect
viru
elimin
addit
diagnost
valu
antibodi
test
identifi
individu
develop
immun
infect
may
protect
subsequ
reinfect
well
defin
monitor
extent
viru
spread
popul
herd
immun
societ
level
antibodi
test
may
therefor
relev
follow
set
diagnosi
patient
seek
medic
attent
seven
onset
symptom
ii
contact
trace
iii
determin
potenti
immun
risk
infect
iv
seroepidemiolog
studi
understand
extent
spread
due
urgenc
demand
lot
serolog
test
rapidli
develop
made
avail
market
limit
valid
clinic
sampl
retrospect
studi
evalu
sensit
specif
commerci
avail
immunoassay
detect
antibodi
specif
viru
patient
serum
sampl
use
studi
submit
routin
serolog
laboratori
staten
serum
institut
diagnost
purpos
case
serum
sampl
obtain
patient
n
admit
intens
care
unit
hospit
denmark
infect
confirm
viral
nucleic
acid
detect
sampl
respiratori
tract
control
serum
sampl
includ
archiv
anonym
serum
sampl
obtain
healthi
blood
donor
year
histori
infect
n
recent
travel
histori
sera
patient
acut
viral
respiratori
tract
infect
caus
coronavirus
n
noncoronavirus
n
sera
patient
posit
dengu
viru
n
cytomegaloviru
cmv
n
epstein
barr
viru
ebv
n
one
patient
posit
cmv
ebv
wantai
ab
elisa
beij
wantai
biolog
pharmaci
enterpris
beij
china
cat
perform
accord
manufactur
instruct
assay
base
doubleantigen
sandwich
principl
detect
total
antibodi
bind
spike
protein
receptor
bind
domain
rbd
human
serum
plasma
briefli
undilut
serum
sampl
ad
well
coat
recombin
antigen
incub
minut
well
wash
five
time
follow
addit
hrpconjug
antigen
subsequ
incub
minut
well
wash
five
time
chromogen
solut
ad
follow
minut
incub
reaction
stop
result
absorb
read
micropl
reader
nm
refer
nm
cutoff
valu
posit
result
calcul
accord
manufactur
instruct
ad
calcul
neg
control
valu
igg
iga
elisa
euroimmun
medizinisch
labordiagnostika
germani
cat
ei
g
ei
respect
perform
accord
manufactur
instruct
two
separ
semiquantit
elisa
either
iga
igg
antibodi
spike
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
highest
wantai
total
ab
elisa
respect
compar
euroimmun
iga
elisa
respect
igg
elisa
respect
euroimmun
iga
elisa
crossreact
primarili
serum
contain
antibodi
one
respiratori
viru
associ
presenc
adenoviru
antibodi
dengu
viru
antibodi
tabl
euroimmun
igg
elisa
crossreact
serum
sampl
posit
human
coronaviru
two
sampl
adenoviru
antibodi
roc
auc
analysi
present
good
paramet
diagnost
power
individu
test
compar
differ
elisa
kit
figur
wantai
total
antibodi
kit
highest
measur
ci
follow
euroimmun
iga
elisa
ci
euroimmun
igg
elisa
ci
four
poc
test
test
case
serum
sampl
sensit
rank
order
autobio
diagnost
dynamik
biotechnolog
ctk
biotech
artron
laboratori
decemb
novel
coronaviru
caus
sever
acut
respiratori
symptom
emerg
wuhan
china
world
health
organ
term
diseas
coronaviru
diseas
caus
viru
sever
acut
respiratori
syndrom
coronaviru
april
viru
spread
countri
territori
confirm
case
death
worldwid
present
epidem
within
major
countri
yet
reach
peak
number
case
death
predict
rise
come
week
month
accur
diagnosi
essenti
ensur
appropri
patient
care
also
facilit
identif
infect
peopl
includ
asymptomat
carrier
need
isol
limit
viru
spread
recommend
nucleic
acid
detect
respiratori
sampl
diagnosi
unfortun
face
rapidli
grow
epidem
worldwid
increas
demand
diagnost
test
led
critic
shortag
oper
materi
respiratori
sampl
collect
within
molecular
diagnost
workflow
imped
rapid
larg
scale
test
necess
control
epidem
moreov
heterogen
respiratori
sampl
materi
anatom
locat
sampl
collect
exampl
throat
swab
saliva
endotrach
aspir
affect
sensit
viral
nucleic
acid
test
overal
urgent
need
identifi
altern
diagnost
mean
antibodi
test
either
use
enzymelink
immunosorb
assay
elisa
pointofcar
poc
later
flow
immunoassay
may
overcom
challeng
antibodi
detect
serum
approxim
patient
earli
seven
day
onset
symptom
seroconvers
rate
rapidli
increas
day
recent
studi
antibodi
test
shown
sensit
viral
nucleic
acid
detect
approxim
eight
day
covidprotein
subunit
detect
human
serum
plasma
briefli
dilut
serum
sampl
ad
well
coat
recombin
antigen
incub
minut
well
wash
three
time
follow
addit
hrpconjug
antihuman
iga
igg
subsequ
incub
minut
well
wash
three
time
chromogen
solut
ad
follow
minut
incub
room
temperatur
reaction
stop
result
absorb
read
micropl
reader
nm
refer
nm
ratio
extinct
sampl
calibr
plate
calcul
accord
manufactur
recommend
ratio
consid
neg
borderlin
posit
howev
sensit
specif
use
stringent
cutoff
valu
posit
result
valu
consid
neg
six
poc
test
rapid
detect
antibodi
blood
serum
plasma
evalu
iggigm
test
recommend
sampl
volum
serum
ad
specimen
well
individu
test
cassett
follow
addit
suppli
buffer
buffer
volum
differ
manufactur
ad
accordingli
three
drop
two
drop
two
drop
two
drop
respect
result
read
visual
minut
weak
signal
igm
igg
togeth
separ
consid
posit
sensit
defin
proport
patient
correctli
identifi
infect
initi
diagnos
use
nucleic
acid
detect
respiratori
sampl
specif
defin
proport
immun
studi
particip
accur
identifi
neg
clinic
accuraci
elisa
assay
examin
use
receiv
oper
characterist
roc
plot
graphpad
prism
version
graphpad
softwar
san
diego
ca
usa
roc
area
curv
auc
calcul
fraction
correctli
identifi
posit
fraction
fals
identifi
posit
determin
accord
manufactur
cutoff
valu
posit
result
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
three
commerci
cemark
elisa
assay
detect
antibodi
evalu
use
serum
sampl
pcrposit
case
control
serum
sampl
twenti
nine
case
posit
antibodi
least
one
three
elisa
assay
one
case
posit
iga
result
detect
anoth
case
antibodi
respons
neg
test
distanc
data
point
manufactur
recommend
cutoff
valu
confid
assign
posit
neg
statu
differ
three
assay
figur
distribut
posit
neg
data
point
distinct
wantai
total
ab
assay
cutoff
valu
control
sera
sampl
allow
unequivoc
interpret
convers
euroimmun
iga
igg
assay
data
less
distinct
separ
result
grey
zone
borderlin
data
point
posit
neg
statu
could
assign
case
control
sera
borderlin
inconclus
data
point
sensit
specif
shown
tabl
sensit
wantai
total
ab
elisa
equival
euroimmun
iga
elisa
greater
observ
euroimmun
igg
elisa
specif
wantai
total
ab
elisa
compar
euroimmun
iga
igg
elisa
respect
posit
predict
valu
neg
predict
valu
posit
predict
valu
test
neg
predict
valu
respect
acro
biotech
evalu
five
case
serum
sampl
specif
one
case
serum
sampl
test
hangzhou
alltest
biotech
test
posit
igm
igg
specif
six
poc
test
evalu
primarili
control
sampl
show
crossreact
elisa
assay
number
control
sera
test
vari
differ
poc
test
tabl
poc
test
manufactur
dynamik
biotechnolog
ctk
biotech
autobio
diagnost
artron
laboratori
specif
wherea
test
acro
biotech
hangzhou
alltest
biotech
specif
respect
latter
two
test
crossreact
observ
igm
acro
biotech
test
crossreact
control
serum
sampl
human
coronaviru
patient
evalu
sensit
assay
differ
stage
diseas
case
sera
group
accord
durat
diseas
earli
phase
day
onset
diseas
symptom
middl
phase
day
onset
diseas
symptom
late
phase
day
onset
diseas
symptom
sensit
assay
rang
earli
phase
sampl
middl
phase
sampl
late
phase
figur
earli
phase
wantai
total
ab
elisa
sensit
plateau
day
ill
durat
igg
elisa
lowest
sensit
three
phase
show
distinct
increas
consecut
phase
ie
earli
phase
middl
phase
late
phase
four
poc
test
evalu
accord
ill
durat
often
weakli
posit
detect
igg
igm
earli
phase
data
shown
sensit
compar
wantai
total
ab
elisa
euroimmun
iga
elisa
three
phase
earli
phase
case
sampl
neg
total
ab
igg
posit
iga
elisa
determin
agreement
differ
elisa
poc
test
evalu
proport
case
sera
share
result
two
assay
calcul
despit
compar
sensit
certain
assay
test
necessarili
give
result
instanc
figur
test
concord
dynamik
biotechnolog
ctk
biotech
poc
test
figur
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
present
studi
three
commerci
elisa
assay
six
poc
rapid
test
evalu
use
sera
hospit
adult
patient
pcrconfirm
diagnos
collect
control
serum
sampl
taken
emerg
viru
china
decemb
overal
wantai
total
ab
elisa
superior
sensit
specif
compar
euroimmun
iga
igg
elisa
poc
test
vari
notabl
best
perform
observ
test
produc
autobio
diagnost
follow
test
produc
dynamik
biotechnolog
ctk
biotech
differ
observ
sensit
specif
total
antibodi
test
antibodi
type
elisa
correspond
previou
report
notabl
lower
sensit
igg
detect
agreement
observ
euroimmun
igg
elisa
present
studi
wantai
igg
euroimmun
igg
elisa
could
compar
due
unavail
former
possibl
overal
lower
sensit
igg
elisa
may
univers
occurr
rather
manufactur
depend
warrant
investig
addit
lower
sensit
euroimmun
iga
igg
elisa
also
prone
crossreact
neg
sera
describ
present
studi
separ
analysi
betavers
assay
differ
assay
may
part
explain
antigen
target
elisa
format
use
kit
detect
antibodi
subunit
spike
protein
howev
wantai
total
ab
elisa
target
rbd
within
rbd
repres
approxim
subunit
thu
epitop
may
recogn
crossreact
epitop
outsid
domain
absent
furthermor
rbd
highli
divers
betacoronavirus
may
reduc
likelihood
crossreact
circul
coronavirus
moreov
wantai
total
ab
elisa
use
antigenantibodyantigen
peroxidas
format
wherea
euroimmun
elisa
employ
antigenantibodyantibodi
peroxidas
format
specif
former
determin
singl
antibodi
wherea
latter
second
antibodi
may
introduc
addit
specif
antigenantibodyantibodi
format
requir
distinguish
specif
antibodi
type
may
necessarili
lead
decreas
specif
shown
inhous
elisa
clinic
sensit
igm
earli
diagnosi
current
unclear
igm
consist
appear
igg
counterpart
studi
report
detect
sarscov
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
conclus
find
show
elisa
format
sensit
detect
total
rbdspecif
antibodi
higher
assay
detect
spikespecif
iga
igg
import
note
presenc
antibodi
necessarili
correspond
protect
infect
diseas
order
defin
antibodymedi
protect
investig
virusspecif
antibodi
function
includ
neutral
fcmediat
effector
function
need
seroepidemiolog
investig
togeth
longitudin
studi
sequenti
sampl
taken
patient
necessari
character
spread
viru
long
term
protect
antibodi
measur
due
compar
poorer
assay
perform
initi
round
test
test
suspend
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
